Cargando…

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer

Sequential chemotherapy may improve treatment efficacy avoiding the additive toxicity associated with concomitant polichemotherapy in hormone-refractory prostate cancer (HRPC). Forty patients received docetaxel 30 mg m(−2) intravenous (i.v.), weekly, plus estramustine 280 mg twice daily for 12 weeks...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galli, L, Fontana, A, Galli, C, Landi, L, Fontana, E, Antonuzzo, A, Andreuccetti, M, Aitini, E, Barbieri, R, Di Marsico, R, Falcone, A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360275/ https://www.ncbi.nlm.nih.gov/pubmed/18026196 http://dx.doi.org/10.1038/sj.bjc.6604090

Ejemplares similares

Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience
por: Nakano, Kazuhiko, et al.
Publicado: (2012)

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study
por: Tibaldi, C, et al.
Publicado: (2008)

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
por: Collins, R, et al.
Publicado: (2006)

Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans.
por: Bergenheim, A. T., et al.
Publicado: (1993)

Estramustine binding protein and anti-proliferative effect of estramustine in human glioma cell lines.
por: von Schoultz, E., et al.
Publicado: (1988)

Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study
por: Carles, J, et al.
Publicado: (2007)

Effects of radiotherapy and estramustine on the microvasculature in malignant glioma
por: Johansson, M, et al.
Publicado: (1999)

Marked leukocytosis in response to estramustine phosphate in a hormone-refractory prostate cancer patient
por: Morita, Tatsuo
Publicado: (2010)

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.
por: Speicher, L. A., et al.
Publicado: (1991)

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer
por: Albrecht, W, et al.
Publicado: (2004)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
por: DiPaola, Robert S, et al.
Publicado: (2010)

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.
por: Hernes, E. H., et al.
Publicado: (1997)

A Multicenter, Randomized Clinical Trial Comparing the Three-Weekly Docetaxel Regimen plus Prednisone versus Mitoxantone plus Prednisone for Chinese Patients with Metastatic Castration Refractory Prostate Cancer
por: Zhou, Tie, et al.
Publicado: (2015)

Comparison of Ketoconazole and Estramustine for Treating Patients with Castration-Resistant Prostate Cancer
por: Yun, Bu Hyeon, et al.
Publicado: (2011)

Computerized detection of morphological changes to glioma cells during estramustine and ion-channel blocker perifusion.
por: Behnam-Motlagh, P., et al.
Publicado: (1997)

Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines—An Isobolographic Analysis
por: Wróblewska-Łuczka, Paula, et al.
Publicado: (2022)

Cytosine Arabinoside and Mitoxantrone Followed by Second Allogeneic Transplant for the Treatment of Children With Refractory Juvenile Myelomonocytic Leukemia
por: Patel, Sachit A., et al.
Publicado: (2014)

Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region
por: Miranda, Enrique, et al.
Publicado: (2012)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Comparison of High-Dose Cytarabine, Mitoxantrone, and Pegaspargase (HAM-pegA) to High-Dose Cytarabine, Mitoxantrone, Cladribine, and Filgrastim (CLAG-M) as First-Line Salvage Cytotoxic Chemotherapy for Relapsed/Refractory Acute Myeloid Leukemia
por: Patzke, Ciera L., et al.
Publicado: (2020)

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
por: Maj-Hes, Agnieszka, et al.
Publicado: (2021)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain--suggesting an apoptotic cell death.
por: Vallbo, C., et al.
Publicado: (1995)

Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone
por: Altmann, Sharon E., et al.
Publicado: (2012)

A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
por: Resta, Lee P., et al.
Publicado: (2010)

Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis
por: Qin, Zhiqiang, et al.
Publicado: (2016)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
por: Narita, Shintaro, et al.
Publicado: (2012)

Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.
por: Rentsch, K. M., et al.
Publicado: (1997)

A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
por: Vasile, E, et al.
Publicado: (2009)

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia
por: Zeidner, Joshua F., et al.
Publicado: (2021)

Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone
por: Lee, Chee Khoon, et al.
Publicado: (2013)

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

Morning stiffness response with delayed-release prednisone after ineffective course of immediate-release prednisone
por: Alten, R, et al.
Publicado: (2015)

Pharmacokinetics of mitoxantrone in cancer patients treated by high-dose chemotherapy and autologous bone marrow transplantation.
por: Richard, B., et al.
Publicado: (1992)

PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate
por: Ruperto, N, et al.
Publicado: (2013)

Estramustine Phosphate Inhibits TGF-β-Induced Mouse Macrophage Migration and Urokinase-Type Plasminogen Activator Production
por: Mojsilovic, Sonja S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k3vasrq9ijucckome712iuvknf